New funding and ad support aim to ease capital gaps for small wedding businesses
Updated
February 24, 2026 2:55 PM
Mannequins display white wedding dresses in a bridal shop window. PHOTO: ADOBE STOCK
The Knot Worldwide, a global wedding technology platform and vendor marketplace, has launched a new grant initiative aimed at small businesses in the wedding industry.
The company, which operates brands such as The Knot and WeddingWire, connects couples with wedding professionals and provides tools to help vendors grow. It says the new WeddingPro Grant Program is designed to address a persistent challenge in the sector: access to capital.
Under the program, up to US$500,000 will be distributed to U.S.-based wedding professionals who run small businesses. The support will come in the form of financial grants, advertising credits on WeddingPro and mentorship. Selected businesses will also receive access to education resources and community support through the company’s network.
The move comes at a time when many wedding businesses remain small and resource-constrained. According to the company’s State of the Vendor Report, more than half of wedding businesses employ fewer than ten people. Three in four professionals surveyed said adaptability is critical to long-term success, while flexible funding remains a barrier. The grant program is positioned as a response to that funding gap.
“Our mission at The Knot Worldwide is to help the nearly 900,000 small businesses on our global platforms get discovered through our centralized vendor marketplace as well as give them the tools and resources to grow their business,” said Raina Moskowitz, Chief Executive Officer, The Knot Worldwide. “We consistently hear from our wedding professionals that access to capital is a barrier to getting started in the industry. With our new WeddingPro Grant Program, we will provide access to both capital and critical support services such as mentorship and education that will enable small business owners to further grow and scale.”
The application window opens on February 23 and closes on March 27. Winners are expected to be notified by May 2026, subject to eligibility verification and compliance with the official rules.
The program is open to U.S. wedding professionals who operate small businesses, have been in business for at least six months, can demonstrate an active revenue stream and earn at least 50% of their revenue from weddings. Applicants must submit a short form and a video outlining their business and how they would use the grant funds over the next 12 to 24 months. They can choose whether they prefer a monetary grant or free advertising support on WeddingPro.
To execute the program, The Knot Worldwide has partnered with the Global Entrepreneurship Network, which works with entrepreneurs worldwide. The company says the initiative builds on earlier efforts to support vendors on its platform, which includes about 200,000 wedding professionals in the United States. Its impact will depend on how effectively the support reaches the businesses that need it most. The real measure will be whether it helps them achieve steady, sustainable growth.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.